- Jounce Therapeutics Inc JNCE announced results from the pre-planned data review of the INNATE Phase 2 Trial of JTX-8064 and pimivalimab in patients with advanced solid tumors.
- Data exhibited that patients in the ovarian cancer combination cohort with platinum-resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review.
- In this cohort, 35 patients with third- and fourth-line platinum-resistant ovarian cancer were treated with JTX-8064 and Jounce's PD-1 inhibitor, pimivalimab.
- There were five responders, four of whom are confirmed, with all five patients remaining on study for over six months with continued tumor reduction over time.
- In patients with one to six prior lines of therapy for ovarian cancer, pembrolizumab monotherapy demonstrated a response rate of 8.5%, with a duration of response of 10.2 months.
- Two of the five responders in INNATE have a PD-L1 score of zero, indicating a low likelihood of response to a PD-1 inhibitor.
- The combination was well tolerated with <10% of patients reporting Grade 3 or greater related adverse events.
- In addition to the patients with ovarian cancer, both durable responses and stable disease have occurred in patients with renal cell carcinoma, biliary tract cancer, and first-line and second/third-line head and neck squamous cell carcinoma.
- As previously announced, Jounce is seeking to partner JTX-8064.
- Recently, the company confirmed receiving Concentra Biosciences LLC's unsolicited and non-binding proposal to acquire 100% of the equity of Jounce.
- JNCE Price Action: Jounce Therapeutics shares are up 2.24% at $1.60 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
